Loading
Structure Therapeutics Inc. Stock: price and insider trades · United States
US·Mcap US$1.6B
Structure Therapeutics Inc.: what insiders have been doing
This page follows insider dealings at Structure Therapeutics Inc. as filed with SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Structure Therapeutics Inc. logged 24 filings by 10 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 24 filings, this issuer sits above that mark.
No insider has bought Structure Therapeutics Inc. shares on the open market in the past twelve months. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
54
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Analyst consensus: bullish or bearish?
Analysts rate Structure Therapeutics Inc. Strong Buy (bullish), based on 15 analysts. Average price target: US$105.78.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$22.31
Analyst consensus
15 analystsStrong buy
US$70.00Target US$105.78(+374%)US$145.00
Income statement
EBITDA-US$185.5M
Net income-US$141.2M0.0% margin
Valuation
PER (forward)-10.6x
P/Book1.2x
Beta-1.37
Balance sheet & cash
Market capUS$1.6B
Total debtUS$6.5M
Free Cash Flow-US$225.8M
Debt / Equity0%
Profitability & ownership
ROE-20.2%
ROA-14.9%
% insiders3.1%
% institutions97.7%
Last declaration on 22 September 2026
Declarations54 total
10,626 shares@ US$11.670.0048% mcap28.2% of flowOrdinary SharesSEC:0002037144-26-000004:0
12,024 shares0Ordinary SharesSEC:0002037144-26-000004:1
4,008 shares@ US$35.000.0054% mcap100.0% of flowCommonSEC144:0001950047-26-009722
11,817 shares0Ordinary SharesSEC:0001962926-26-000008:1
11,817 shares@ US$0.340.0002% mcap0.7% of flowOrdinary SharesSEC:0001962926-26-000008:0
140,766 shares0Ordinary SharesSEC:0002148420-26-000006:0
11,817 shares0Ordinary SharesSEC:0001962926-26-000007:1
11,817 shares@ US$0.340.0002% mcap0.7% of flowOrdinary SharesSEC:0001962926-26-000007:0
23,634 shares0Ordinary SharesSEC:0001962926-26-000006:1
23,634 shares@ US$0.340.0003% mcap1.4% of flowOrdinary SharesSEC:0001962926-26-000006:0
35,512 shares@ US$48.160.044% mcap100.0% of flowCommonSEC144:0001950047-26-006512
184,614 shares0Ordinary SharesSEC:0001712069-26-000007:0
75,897 shares0Ordinary SharesSEC:0002037144-26-000003:0
47,706 shares0Ordinary SharesSEC:0001801842-26-000003:0
260,217 shares0Ordinary SharesSEC:0001698149-26-000003:0
43,368 shares0Ordinary SharesSEC:0001962926-26-000003:0
53,454 shares@ US$20.9988.0% of flowOrdinary SharesSEC:0001698149-26-000002:0
11,826 shares@ US$20.9955.4% of flowOrdinary SharesSEC:0002037144-26-000002:0
18,735 shares@ US$20.9966.3% of flowOrdinary SharesSEC:0001962926-26-000002:0
4,836 shares@ US$20.9968.7% of flowOrdinary SharesSEC:0001801842-26-000002:0
6,021 shares@ US$7.743331.3% of flowOrdinary SharesSEC:0001801842-25-000004:0
25 of 54 declarations
About Structure Therapeutics Inc.
Structure Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for metabolic diseases and health-related disorders. It employs a drug discovery platform to identify new therapies.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
